Immunotherapy for Metastatic Bladder Carcinoma

Rümeysa ÇOLAKa , Deniz TURALa
aBakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Medical Oncology, İstanbul, Türkiye

Çolak R, Tural D. Immunotherapy for metastatic bladder carcinoma. In: Şendur MAN, ed. Current Immunotherapy Landscape for Solid Tumors. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.99-105.

ABSTRACT
Urothelial bladder cancer (BC) is one of the most fatal cancers, with a five-year survival rate of 5% in patients with metastatic disease. Since 2016, five immune checkpoint inhibitors (ICIs) have been approved by the Food and Drug Administration (FDA) in different settings, i.e., first-line, maintenance and second-line treatment, while several trials are still ongoing in the perioperative context. We reviewed the results from clinical trials that investigated how well certain types of anticancer drugs called PD-1/PD-L1 inhibitors worked in patients with bladder cancer.

Keywords: Immune checkpoint inhibitors ; urinary bladder neoplasms

Referanslar

  1. Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol. 2015;7:65-79. [Crossref]  [PubMed]  [PMC]
  2. Hussain SA, Birtle A, Crabb S, Huddart R, Small D, Summerhayes M, et al. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. Eur Urol Oncol. 2018;1(6):486-500. [Crossref]  [PubMed]
  3. Hoffman-Censits J, Wong YN. Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma. Clin Genitourin Cancer. 2015;13(4):302-8. [Crossref]  [PubMed]  [PMC]
  4. Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. J Urol. 2016;195(2):254-63. [Crossref]  [PubMed]
  5. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. J Clin Oncol. 2023;41(23):3881-90. [Crossref]  [PubMed]
  6. Roviello G, Catalano M, Santi R, Palmieri VE, Vannini G, Galli IC, et al. Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. Cancers (Basel). 2021;13(17):4411. [Crossref]  [PubMed]  [PMC]
  7. U. S. F. and D. Administration, "Tecentriq (atezolizumab) prescribing information." FDA, 2016. Atezolizumab: US Food and Drug Administration Prescribing Label. [Link]
  8. U. S. Food, "Drug Administration. Keytruda (pembrolizumab) prescribing information." 2017. Pembrolizumab: United States Food and Drug Administration Prescribing Label [Link]
  9. Squibb BM. "OPDIVO (nivolumab) prescribing information. US Food and Drug Administration, December, 2020." Nivolumab: US Food and Drug Administration (FDA) Prescribing Label [Link]
  10. H. D. are Made and P. List, "European Medicines Agency Validates Application for BAVENCIO®(avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma." Avelumab injection. United States Prescribing Information. US National Library of Medicine. [Link]
  11. Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-30. [Crossref]  [PubMed]
  12. Powles TB, Perez Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+ P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann. Oncol. 2023;34(4):S1557-S8. [Crossref]
  13. van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al.; CheckMate 901 Trial Investigators. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023;389(19):1778-89. [Crossref]  [PubMed]
  14. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454-61. Erratum in: J Clin Oncol. 2010;28(1):182. Winquist, Eric [added]. [Crossref]  [PubMed]
  15. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191-9. [Crossref]  [PubMed]  [PMC]
  16. Grivas P, Park SH, Voog E, Caserta C, Gurney H, Bellmunt J, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol. 2023;84(1):95-108. [Crossref]  [PubMed]
  17. Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, et al. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol. 2023;41(1):22-31. [Crossref]  [PubMed]  [PMC]
  18. Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, et al.. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):872-82. Erratum in: Lancet Oncol. 2021;22(6):e239. [Crossref]  [PubMed]
  19. Bellmunt J, Lernert SP, Shah SM. Treatment of metastatic urothelial cancer of the bladder and urinary tract. UpToDate. 2021.
  20. Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483-92. [Crossref]  [PubMed]
  21. Vuky J, Balar AV, Castellano D, O'Donnell PH, Grivas P, Bellmunt J, et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2020;38(23):2658-66. [Crossref]  [PubMed]
  22. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al.; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76. Erratum in: Lancet. 2017;390(10097):848. [Crossref]  [PubMed]
  23. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-20. [Crossref]  [PubMed]
  24. Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E, et al.; IMvigor130 Study Group. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547-57. [Crossref]  [PubMed]
  25. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al.; KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376(11):1015-26. [Crossref]  [PubMed]  [PMC]
  26. Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, Juco J, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18(2):212-20. [Crossref]  [PubMed]
  27. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312-22. [Crossref]  [PubMed]
  28. Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, et al. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J Clin Oncol. 2017;35(19):2117-24. [Crossref]  [PubMed]  [PMC]
  29. Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19(1):51-64. Erratum in: Lancet Oncol. 2018;19(7):e335. [Crossref]  [PubMed]
  30. Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al.; DANUBE study investigators. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574-88. Erratum in: Lancet Oncol. 2021;22(1):e5. [Crossref]  [PubMed]
  31. Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748-57. Erratum in: Lancet. 2018;392(10156):1402. [Crossref]  [PubMed]